v3.26.1
SEGMENT INFORMATION (Tables)
6 Months Ended
Jun. 30, 2026
SEGMENT INFORMATION  
Schedule of disaggregated amounts of research and development expenses

  ​ ​ ​

For the six months ended June 30,

  ​ ​ ​

2025

  ​ ​ ​

2026

US$

US$

Direct research and development expenses(a)

 

3,940,166

 

5,575,874

Indirect research and development expenses(b)

Payroll and other related costs of personnel

 

6,340,610

 

6,773,495

Lab supplies and other research and development expenses

 

1,734,408

 

1,615,298

Total indirect research and development expenses

 

8,075,018

 

8,388,793

Total research and development expenses

 

12,015,184

 

13,964,667

Note (a): Direct research and development expenses consist principally of: (1) costs related to clinical trials such as payments to CRO, CDMO, investigators, and clinical trial sites that conduct the clinical studies; and (2) costs to develop the product candidates, including costs related to product testing.

Note (b): Indirect research and development expenses are not allocated directly to each program, and primarily consist of compensation and other personnel related costs, overhead and infrastructure costs to maintain our facilities, and other costs related to activities that benefit multiple projects.